- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | OS Therapies files $100M mixed securities shelf | 1 | Seeking Alpha | ||
| 07.08. | OS Therapies Announces Statistically Significant Positive Interim 2-Year Overall Survival Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma | 165 | Newsfile | 66.6% of OST-HER2 treated patients achieved 2-year overall survival compared with 40% in the historical control group (p = 0.0046)FDA issues Biologics Licensing Application (BLA) number for OST-HER2... ► Artikel lesen | |
| 07.08. | OS Therapies Receives Positive Feedback from UK MHRA Scientific Advice Meeting and Submits Innovative Licensing and Access Pathway (ILAP) Request for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma | 205 | Newsfile | MHRA seeks to harmonize UK & US regulatory review via Project OrbisEMA Rapporteur Scientific Advice Meeting scheduled for October 2025New York, New York--(Newsfile Corp. - August 7, 2025) - OS Therapies... ► Artikel lesen | |
| 04.08. | OS Therapies Inc - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 14.07. | OS Therapies Inc - 8-K, Current Report | 4 | SEC Filings | ||
| 14.07. | OS Therapies Closes $4.2 Million in Warrant Exercise Inducement and Exchange Offer | 258 | Newsfile | Cash runway extended through 2026, beyond September 30, 2026 sunset date for rare pediatric priority review voucher (PRV) program Additional funding allows Company to advance strategic alternatives... ► Artikel lesen | |
| OS THERAPIES Aktie jetzt für 0€ handeln | |||||
| 10.07. | OS Therapies Provides Clinical & Global Regulatory Updates | 250 | Newsfile | End of Phase 2 Meeting with FDA scheduled for August 27, 2025 to review OST-HER2 recurrent, pulmonary metastatic osteosarcoma programScientific Advice Meetings confirmed with global regulators in major... ► Artikel lesen | |
| 03.07. | OS Therapies Shares Climb As FDA Grants End Of Phase 2 Meeting For OST-HER2 Program In Osteosarcoma | 1 | RTTNews | ||
| 03.07. | OS Therapies granted FDA end of phase 2 meeting for osteosarcoma drug | 1 | Investing.com | ||
| 03.07. | OS Therapies erhält FDA-Treffen nach Phase 2 für Osteosarkom-Medikament | - | Investing.com Deutsch | ||
| 30.06. | OS Therapies reports positive survival data for osteosarcoma treatment | 1 | Investing.com | ||
| 24.06. | OS Therapies stock surges after positive FDA feedback on OST-HER2 | 1 | Investing.com | ||
| 24.06. | OS Therapies-Aktie steigt nach positiver FDA-Rückmeldung zu OST-HER2 | 1 | Investing.com Deutsch | ||
| 24.06. | OS Therapies erhält positives FDA-Feedback für Osteosarkom-Behandlung | 1 | Investing.com Deutsch | ||
| 24.06. | OS Therapies receives positive FDA feedback for osteosarcoma treatment | 2 | Investing.com | ||
| 24.06. | OS Therapies Inc - 8-K, Current Report | 2 | SEC Filings | ||
| 11.06. | OS Therapies Taps EVERSANA To Launch First New Pediatric Osteosarcoma Treatment In 40 Years | 1 | RTTNews | ||
| 10.06. | OS Therapies kooperiert mit EVERSANA für Krebsmedikamenten-Markteinführung | 1 | Investing.com Deutsch | ||
| 06.06. | OS Therapies Submits Request For RMAT Designation For OST-HER2 | 1 | RTTNews | ||
| 06.06. | OS Therapies seeks FDA regenerative therapy tag for cancer drug | 1 | Investing.com |
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CRISPR THERAPEUTICS | 49,800 | +1,63 % | CRISPR Therapeutics - CRSP: Short Squeeze bei der Schweizer Biotech-Aktie? | Short Float bei 29.37% Seit Jahren keine Gewinne bei CRISPR Therapeutics (CRSP). Insider kauft trotzdem! JETZT Pullback-Setup! CRISPR Therapeutics (CRSP) - ISIN CH0334081137 Rückblick: Die Kombination... ► Artikel lesen | |
| IMMUNIC | 0,721 | +1,98 % | EQS-News: Immunic AG: Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Issuer: Immunic AG
/ Key word(s): Quarter Results
Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update
07.08.2025 / 12:30 CET/CEST
The... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 2,215 | 0,00 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds | King of Prussia, Pennsylvania--(Newsfile Corp. - July 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary... ► Artikel lesen | |
| ANAVEX LIFE SCIENCES | 8,920 | -1,09 % | Anavex Life Sciences Corp.: Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update | Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 19,210 | 0,00 % | Mercury Systems Posts Better-Than-Expected Earnings, Joins Green Dot, Arcturus Therapeutics And Other Big Stocks Moving Higher On Tuesday | ||
| PROTALIX BIOTHERAPEUTICS | 1,470 | +6,52 % | Protalix BioTherapeutics Q2 Earnings Preview | ||
| ZEVRA THERAPEUTICS | 8,100 | +0,62 % | Zevra Therapeutics: Zevra Reports Second Quarter 2025 Financial Results and Corporate Update | Q2 2025 net revenue of $25.9 million, driven by product net revenue of $21.8 million Completed sale of PRV for $150.0 million, bolstering the balance sheet as the Company executes on its commercial... ► Artikel lesen | |
| GEOVAX LABS | 2,685 | -100,00 % | GeoVax Labs: Nasdaq-Rüge wegen Unterschreitung des Mindestkurses | ||
| SCILEX | 21,170 | 0,00 % | Scilex Holding Company (Nasdaq: SCLX) Announces Effectiveness of Registration Statement on Form S-4 for the Proposed Business Combination of Denali Capital Acquisition Corp. and Semnur Pharmaceuticals, Inc. | Denali's registration statement on Form S-4 declared effective by the Securities and Exchange CommissionExtraordinary general meeting of Denali Capital Acquisition Corp. shareholders to approve the... ► Artikel lesen | |
| MEIRAGTX | 7,200 | +0,70 % | MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson's Disease | - This RMAT designation is based on data from 3 clinical studies demonstrating the potential benefit of AAV-GAD as a one-time treatment for Parkinson's disease - RMAT designation includes the benefits... ► Artikel lesen | |
| TENAYA THERAPEUTICS | 0,860 | 0,00 % | Tenaya Therapeutics GAAP EPS of -$0.14 beats by $0.06 | ||
| INVIVYD | 0,789 | 0,00 % | Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection | Attractive safety profile demonstrated across all dosing cohorts and routes of administration (IV, SC, and IM); all reported adverse events (AEs) deemed unrelated or classified as mild to moderate... ► Artikel lesen | |
| UNICYCIVE THERAPEUTICS | 4,405 | 0,00 % | Unicycive Therapeutics, Inc.: Unicycive Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement | LOS ALTOS, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 46,150 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
| BOLT PROJECTS | 14,320 | 0,00 % | Bolt Projects Stock Surges 38% on Strong Q2, $20M Funding; CEO: 'Demand For Vegan Silk Continues To Grow' |
OS THERAPIES INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,870 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OS THERAPIES INC finden Sie auf Wallstreet Online.